Detalhe da pesquisa
1.
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 402(10403): 705-719, 2023 08 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37385278
2.
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial.
Lancet
; 402(10403): 693-704, 2023 08 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37385279
3.
Glycaemic control and macrovascular and microvascular outcomes: A systematic review and meta-analysis of trials investigating intensive glucose-lowering strategies in people with type 2 diabetes.
Diabetes Obes Metab
; 26(6): 2069-2081, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38409644
4.
A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes.
Diabetes Obes Metab
; 26(6): 2017-2028, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38433708
5.
Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: Systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents.
Diabetes Obes Metab
; 26(5): 1837-1849, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38379094
6.
Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - Diabetes: rationale and design.
Am Heart J
; 256: 2-12, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36279931
7.
Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes.
Diabetes Obes Metab
; 25(5): 1385-1397, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36700417
8.
Efficacy and safety of once-weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE-D, AMPLITUDE-L and AMPLITUDE-S randomized controlled trials.
Diabetes Obes Metab
; 25(8): 2084-2095, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37013892
9.
Coordinated Care to Optimize Cardiovascular Preventive Therapies in Type 2 Diabetes: A Randomized Clinical Trial.
JAMA
; 329(15): 1261-1270, 2023 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36877177
10.
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Diabetologia
; 65(12): 1925-1966, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36151309
11.
Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community.
Circulation
; 144(1): 74-84, 2021 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34228476
12.
Vitamin D Supplementation and Prevention of Type 2 Diabetes.
N Engl J Med
; 381(6): 520-530, 2019 08 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31173679
13.
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
Rev Endocr Metab Disord
; 23(5): 979-994, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35838946
14.
Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment.
Diabetes Obes Metab
; 24(12): 2297-2308, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35929480
15.
Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.
Diabetes Obes Metab
; 24(7): 1338-1350, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35373893
16.
Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: A perspective based on the updated evidence.
Diabetes Obes Metab
; 24(11): 2071-2080, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35801339
17.
Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes.
Curr Diab Rep
; 21(10): 41, 2021 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34580767
18.
Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study.
Diabetes Obes Metab
; 23(9): 2177-2182, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34060209
19.
Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.
Diabetes Obes Metab
; 23(7): 1588-1593, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33687748
20.
Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus glucagon-like peptide-1 receptor agonists in people with type 2 diabetes mellitus: A network meta-analysis.
Diabetes Obes Metab
; 23(1): 136-146, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32991041